Literature DB >> 33385749

Myopathy Associated With Statins and SGLT2 - A Review of Literature.

Rahul Gupta, Ryan Alcantara, Tarun Popli, Sugandhi Mahajan, Umair Tariq, Raman S Dusaj, Aaqib H Malik.   

Abstract

Drug-induced myopathy is a well-described clinical entity characterized by muscle damage leading to symptoms ranging from myalgias to rhabdomyolysis and acute kidney injury. Many pharmacotherapies are known to precipitate myopathic symptoms. Recent case reports suggest a potential relationship between the use of sodium/glucose cotransport 2 (SGLT2) inhibitors and onset of myopathy. The pathogenesis of this has yet to be elucidated. The relevance of this association is augmented by the recent popularity of SGLT2 inhibitors as well as the tendency for them to be prescribed alongside statins. This study reviewed the literature on the incidence and mechanism of drug-induced myopathy in patients with type 2 diabetes mellitus who are taking SGLT2 inhibitors with and without the use of statins.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33385749     DOI: 10.1016/j.cpcardiol.2020.100765

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   5.200


  3 in total

1.  A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.

Authors:  Manuela Stella; Erica Biassoni; Chiara Fiorillo; Marina Grandis; Francesca Mattioli; Massimo Del Sette
Journal:  Neurol Sci       Date:  2022-04-07       Impact factor: 3.307

2.  Assessment of the Preventive Effect of L-carnitine on Post-statin Muscle Damage in a Zebrafish Model.

Authors:  Joanna Niedbalska-Tarnowska; Katarzyna Ochenkowska; Marta Migocka-Patrzałek; Magda Dubińska-Magiera
Journal:  Cells       Date:  2022-04-11       Impact factor: 7.666

Review 3.  Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies.

Authors:  Magda Dubińska-Magiera; Marta Migocka-Patrzałek; Damian Lewandowski; Małgorzata Daczewska; Krzysztof Jagla
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.